Introduction: The benefits of rotavirus (RV) vaccination in developed countries have
INTRODUCTION
Rotavirus (RV) infection is a well-known cause of acute gastro-enteritis leading to severe diarrhea in small children. It shows a seasonal pattern in the more temperate climates, resulting in epidemic peaks during winter and spring [1, 2] . As a result pediatric wards are often overwhelmed with a high bed occupancy rate due to diarrheal disease [3] . High rates of infant hospitalization for other conditions that occur in the same period, such as bronchiolitis, can further compound the problem of overcrowding. [4] .
The use of vaccines could help to improve management of this recurrent annual health care problem [5] . Different vaccines have demonstrated a high efficacy against severe disease in infants and young children. Two vaccines are currently on the market at the global level, a two-dose vaccine Rotarix TM (GSK, Rixensart, Belgium) [6, 7] and a three-dose vaccine Rotateq TM (Merck and Co. Inc, Whitehouse Station, New Jersey, United States) [8] . Belgium was one of the first countries in Europe to introduce the RV vaccine with a co-payment scheme [9] . The vaccines have been reimbursed since November 2006 (first Rotarix and subsequently Rotateq, 1 year later) [10] . A high vaccine uptake (above 85%) in the first year of introduction of RV vaccination has been maintained over the years [9, 11] . To date, the vaccination program has had more than 7 years' impact on the local health care system.
In 2007, we initiated the RotaBIS (Rotavirus Belgian Impact Study) study. This project annually collects retrospective data for the past year on RV testing linked to the hospitalization of children aged under 5 years in 11 hospitals located all over Belgium [9] .
Based on RotaBIS, we reported last year on the general effect the vaccines have had on hospitalization, expressing the number of positive test results for RV by age and year and comparing the pre-versus the post-vaccination periods [12] . The results demonstrated sustained vaccine-associated protection over time, i.e., a reduction of RV-related hospitalizations observed after 7 years of around 75%, with a high herd protection level of 26.5% in the first year of the vaccine introduction. In addition, data on many other parameters were systematically collected during the whole follow-up period of the RotaBIS project. These additional data are now analyzed in the present study to address further questions on the impact of the vaccine on RV-induced nosocomial infections [13] , the average duration of hospital stay being for a certain period a surrogate marker for disease severity [14] , a potential more pronounced age shift of RV disease after the introduction of the vaccine [15] , and the sustainability of the vaccine impact (VI) over time [12] .
Based on the data available since 2005, we have attempted to investigate whether the total value of the RV vaccine extends beyond the reduction in hospitalization rate and the generation of a high level of herd protection in the early period of the vaccine introduction.
Information on these additional questions could help to test earlier conclusions that RV vaccination could improve quality of care (QoC) in the hospital environment, as previously suggested [16] .
METHODS

Data Source
The RotaBIS is a retrospective hospital database study (ClinicalTrials.gov identifier, NCT01563146) previously published [9] . To measure the relative importance of the disease as a function of age that may shift over time after vaccine introduction, we calculated the proportional distribution of the disease over the different age groups in each year. We then plotted on a graph the proportional results per age group in each year and observed shifts in those proportions.
Assumptions
A few assumptions underlie the comparison of the annual number of RV-positive tests. One assumption is that the catchment area of each of the participating centers remained the same across the whole observation period of 8 years.
Another assumption is that no change occurred during the period in the disease management behavior of testing children up to 5 years old for RV disease. This means that if fewer tests were performed after the introduction of the vaccine, this is mainly due to fewer suspected cases presenting to the hospital unit and not to a change in behavior of physicians who may have decided to perform RV tests less frequently after vaccine introduction. Therefore, the most relevant comparison between the years is the accumulated number of RV-positive tests and not the proportion of RV-positive tests per year. A third assumption is that during the whole observation period of 8 years there was no change in the criteria for hospitalizing patients with rotavirus disease, given that hospital beds were becoming unoccupied during the peak period after the vaccine had been introduced. Reduced bed occupancy could become an incentive for trying to get those beds occupied by changing the admission criteria.
Statistics
Results were tested for statistical significance using Chi-square tests for the trend of proportional and absolute data over the years. Non-parametric rank testing (Kruskal-Wallis test and Mann-Whitney test) or ANOVA testing after a normality check of the data distribution was used for comparing the values. If not normally distributed, log-norm transformation was applied. 95% confidence intervals (CI) were measured for VI values using the Wilson method [18] . The statistical tests were performed with GraphPad Prism 6.2 for Windows, GraphPad Software, La Jolla California USA, www.graphpad.com. The cutoff value for significance was p = 0.05. Figure 1 and Table 1 
RESULTS
RV-induced Nosocomial Infections
Hospital Bed Occupancy and Length of Stay
The above data indicated a dramatic reduction in the number of nosocomial infections after the introduction of the vaccine. We investigated the contribution of rotavirus to bed days occupied during the peak period of rotavirus disease pre-vaccination and a few years after the vaccine was introduced. Table 2 summarizes the collected numbers for 2005 pre-vaccination and 2012 post-vaccination (there were statistically significant differences 
Overall Average Duration
The overall average duration of a hospital stay for an RV-induced diarrhea event also decreased from 7.62 to 5.77 days, which is close to a 2-day average gain per event, (ANOVA testing after log-normal transformation, F(7, 4389) = 7.706, 
By Source of Infection
When the hospital duration is split by source of infection (community-acquired or nosocomial), the changes over the years in average duration were much less pronounced (see Table 3 ).
However, the average difference in duration between community-acquired (non-nosocomial) and nosocomial RV-associated hospital stay exceeded 10 days when the total hospital length of stay was considered for nosocomial infection. If only the RV-specific period of nosocomial infection was considered, the average difference was reduced to 4-5 days, with average durations of 5 and 10 days, respectively, for community-acquired and nosocomial RV-associated hospital stay (see Table 3 ).
Age Shift
Age had an influence on the duration of RV-induced hospital stay, especially for nosocomial infection, as shown in Vaccine Impact Over Time Figure 6 shows the observed VI on RV-induced hospitalization over time by birth cohort and age group when compared with the pre-vaccination period. No trend for reduced VI was seen over time within each separate age group. The overall results in Fig. 6 calculate the average VI per year, and the 95% CI of the mean calculated for each year overlaps between the lowest and highest average value. However, there was a trend in the reduction of average VI across age groups: 85% in the group aged 3-12 months; 80% in the group aged 1-2 years; 79% in the group aged 2-3 years; 74% in the group aged 3-4 years; and 63% in the group aged 4-5 years. The 95% CI calculated for each age group also overlaps between the highest and the lowest value because of the small numbers in the older age groups (95% CI 76-91% in the highest number of the youngest age group and 22-92% in the oldest age group). In the two oldest age groups, the denominators are small (34 and 10 cases, respectively), leading to a statistically non-significant difference between the age groups. Moreover, hospitalization events are driven by local policy in managing the disease in older children: only 2 of the 11 centers have increased hospitalization rates in the older age groups (Data on file, GSK Vaccines, Wavre, Belgium).
DISCUSSION
The benefits of RV vaccination initially reported in the literature focused on the specific mortality reduction, the decrease in hospitalizations, and the level of herd protection achieved during the first years of vaccination. These phenomena were observed RV rotavirus a ANOVA testing, after transformation, F(7, 3631) = 4.120, p = 0.0002 b ANOVA testing, after transformation, F(7, 740) = 1.827, p = 0.08 c ANOVA testing, after transformation, F(7, 735) = 1.108, p = 0.35 in many countries in Europe and worldwide where vaccination was implemented [19] [20] [21] [22] [23] [24] [25] [26] [27] .
Important additional vaccine benefits that could improve QoC in the hospital environment have been less well documented and reported. It is known that RV is very contagious and that strict hygiene measures cannot always avoid the spread of the virus [28, 29] . The present study indicates that, with the introduction of the vaccine, an important drop of 85% in nosocomial RV infections can be achieved within a few years, together with a reduction in the overall average duration of hospital stay for the disease. It is important to highlight that this overall number should be reported, as it is often the first number available in the absence of being able to differentiate between community-acquired and nosocomial infection. However, the shorter hospital stay seems to be linked to the drop in the number of stay will benefit young patients who are admitted to the hospital for reasons other than diarrhea, as they will now be exposed to a much lower risk of RV infection after the introduction of the vaccine. This will benefit their recovery because the shorter duration of hospital stay will reduce their risk of exposure to any other nosocomial infection source in the hospital environment [16] . . This is called a cohort analysis versus a population analysis [33] . When the results are compared horizontally, good consistency is observed over time within each age group as reported in Fig. 6 . The overall results for each annual birth cohort indicate a slight increase in average VI, but that is due to the last two birth cohorts where data were not available for all the age groups as the individuals in these birth cohorts have not yet attained the older ages.
Considered from a cohort point of view, a trend of VI decrease was observed by age group (also reported in Fig. 6 ). This could be related to a real decrease in VI, a change in management of events among the older children, or a change in testing leading to fewer cases detected and reported in the older age groups. Essentially, two centers out of the eleven had a policy to keep older children in the hospital. Therefore, However, the highest disease burden is in the group aged \2 years, and we observed quite consistent results over time in this group [34] . Finally, information on the vaccination status of the children when they are hospitalized is missing from the study. We are working on ways to collect that information in subsequent runs of the RotaBIS study in the coming years, as it is important to know how many of the hospitalized children were exposed to the vaccine. However, the attractiveness of the RotaBIS study is the low burden in collecting the data, the simple analyses performed and communicated, which sometimes raise additional new research questions, and the opportunity to obtain real-world results that can be compared with model output predictions (for instance, related to herd protection). It gives valuable information on the disease and whether the vaccine maintains its impact over time, which will be useful to decision-makers evaluating RV vaccination programs.
CONCLUSION
The RotaBIS study illustrates additional results that RV vaccination may generate within a hospital environment, besides reducing the number of hospitalizations. The new results focus on the reduction in nosocomial RV infections (-85%), leading to a shorter duration in hospital stay (on average \2 days per RV event). Consequently, better QoC in the hospital environment can be developed, enhancing better health care delivery because of the reduction in bed occupancy during the peak period of rotavirus disease. From the data analyzed over a 6-year period, the VI was maintained over time in the younger age groups.
We observed a slight decrease in the older age groups above 3 years, which could be better explained by changes in local disease and diagnostic management rules than by a real decline in VI.
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